Kazia Therapeutics (KZIA) Competitors $9.30 -0.49 (-5.01%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.40 +0.09 (+1.02%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. LPTX, MEIP, ALVR, FLGC, GELS, VYNE, AIMD, EDSA, SYBX, and ERNAShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Leap Therapeutics (LPTX), MEI Pharma (MEIP), AlloVir (ALVR), Flora Growth (FLGC), Gelteq (GELS), VYNE Therapeutics (VYNE), Ainos (AIMD), Edesa Biotech (EDSA), Synlogic (SYBX), and Eterna Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Its Competitors Leap Therapeutics MEI Pharma AlloVir Flora Growth Gelteq VYNE Therapeutics Ainos Edesa Biotech Synlogic Eterna Therapeutics Kazia Therapeutics (NASDAQ:KZIA) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Which has stronger valuation & earnings, KZIA or LPTX? Kazia Therapeutics has higher revenue and earnings than Leap Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKazia Therapeutics$2.31M4.06-$17.56MN/AN/ALeap TherapeuticsN/AN/A-$81.41M-$1.70-0.24 Does the MarketBeat Community favor KZIA or LPTX? Leap Therapeutics received 213 more outperform votes than Kazia Therapeutics when rated by MarketBeat users. Likewise, 68.37% of users gave Leap Therapeutics an outperform vote while only 53.29% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformKazia TherapeuticsOutperform Votes8153.29% Underperform Votes7146.71% Leap TherapeuticsOutperform Votes29468.37% Underperform Votes13631.63% Does the media refer more to KZIA or LPTX? In the previous week, Kazia Therapeutics had 9 more articles in the media than Leap Therapeutics. MarketBeat recorded 10 mentions for Kazia Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Kazia Therapeutics' score of 0.44 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kazia Therapeutics Neutral Leap Therapeutics Very Positive Which has more volatility & risk, KZIA or LPTX? Kazia Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Do insiders and institutionals hold more shares of KZIA or LPTX? 30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is KZIA or LPTX more profitable? Kazia Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kazia TherapeuticsN/A N/A N/A Leap Therapeutics N/A -116.24%-93.18% Do analysts prefer KZIA or LPTX? Kazia Therapeutics currently has a consensus price target of $57.50, suggesting a potential upside of 518.28%. Leap Therapeutics has a consensus price target of $4.92, suggesting a potential upside of 1,099.48%. Given Leap Therapeutics' higher possible upside, analysts clearly believe Leap Therapeutics is more favorable than Kazia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryKazia Therapeutics beats Leap Therapeutics on 9 of the 14 factors compared between the two stocks. Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.37M$6.87B$5.57B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6319.64Price / Sales4.06262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book-4.726.536.964.60Net Income-$17.56M$143.25M$3.23B$248.06M7 Day Performance64.60%0.18%-1.05%-0.87%1 Month Performance155.49%11.96%8.65%3.58%1 Year Performance-19.15%3.77%33.67%14.04% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics3.5925 of 5 stars$9.30-5.0%$57.50+518.3%-23.2%$9.37M$2.31M0.0012News CoverageAnalyst ForecastShort Interest ↓Gap DownLPTXLeap Therapeutics2.7023 of 5 stars$0.36-5.2%$4.92+1,271.5%-81.4%$14.86MN/A-0.1940Positive NewsGap DownMEIPMEI Pharma1.6827 of 5 stars$2.22-0.9%N/A-21.8%$14.79M$65.30M-0.39100News CoveragePositive NewsShort Interest ↑Gap DownALVRAlloVirN/A$2.90-2.0%N/A-84.2%$14.63MN/A-0.14110News CoverageGap UpFLGCFlora Growth2.7129 of 5 stars$0.64-4.5%$4.00+525.0%-35.4%$14.44M$53.26M-0.65280Positive NewsGap DownGELSGelteqN/A$1.50-6.3%N/AN/A$14.16MN/A0.00N/APositive NewsGap DownVYNEVYNE Therapeutics2.4802 of 5 stars$0.93-2.3%$6.25+573.5%-59.1%$14.12M$605K-1.0830Short Interest ↑High Trading VolumeAIMDAinos1.2014 of 5 stars$0.63-6.5%N/A-38.6%$14.02M$106.21K-0.4940Positive NewsGap DownEDSAEdesa Biotech3.3355 of 5 stars$1.99+1.5%$21.00+955.3%-56.1%$13.98MN/A-1.0620Positive NewsShort Interest ↓SYBXSynlogic1.2712 of 5 stars$1.19+3.7%N/A-23.8%$13.94M$8K-0.2980Upcoming EarningsShort Interest ↑Gap UpERNAEterna Therapeutics0.918 of 5 stars$0.22+0.5%N/A-92.3%$13.66M$535K-0.0310Stock SplitShort Interest ↓Gap Down Related Companies and Tools Related Companies LPTX Alternatives MEIP Alternatives ALVR Alternatives FLGC Alternatives GELS Alternatives VYNE Alternatives AIMD Alternatives EDSA Alternatives SYBX Alternatives ERNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KZIA Stock Free KZIA Stock Alerts